Grifols starts two Phase 3 trials to expand immunoglobulin labels
Tweet Send to a Friend
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
